Table 2.

The percentage of antimicrobial susceptibility of NIs in an Iranian referral pediatrics hospital

Bacteria	Gentamycin	Trimethoprim sulfamethoxazole	Imipenem	Nitrofourantoin	Cefotaxime	Clindamycin	Ampicillin	Ceftazidim	Penicillin
E. coli	58.6%	16.7%	22.2%	100%	12.5%	–	0%	33.3%	22.7%
Enterococcus spp.	23.5%	100%	50%	88.9%	0%	0%	26.9%	–	–
Psuedomonas spp.	23.8%	–	84.2%	–	–	–	–	79.2%	–
P. aureoginosa	72.7%	75%	80.4%	–	62.5%	–	–	80.8%	–
K. pneumonia	37.5%	37.2%	52.9%	33.3%	4.4%	100%	100%	100%	–
CONS	0%	35.4%	–	50%	0%	18.6%	0%	–	0%
S. aureus	0%	78.3%	100%	100%	–	45.5%	–	–	14.3%
Enterobacter spp.	50%	36.4%	100%	0%	14.3%	–	0%	100%	0%
Acinetobacter baumannii	23.7%	9.4%	5.3%	–	2.4%	–	16.7%	5.3%	–
Serratia marcescens	13.6%	100%	100%	–	16%	–	–	100%	–
Stenotrophomonas maltophilia	0%	100%	0%	–	–	–	–	–	0%
Candida spp.	–	–	–	–	–	–	–	–
Streptococcus spp.	–	0%	–	–	–	50%	100%	–	100%
Burkholderia cepacia	33.3%	100%	33.3%	0%	100%	–	0%	66.7%	–
Morganella morganii	50%	100%	–	–	100%	–	–	–	–
Total	41.1%	48.4%	59.4%	63.8%	10.1%	29.6%	29.5%	56.5%	12.6%

Bacteria	Vancomycin	Colistin	Methicillin	Erythromycin	Ciprofloxacin	Tazocin	Linezolide	Amikacin	Cefepime
E. coli	–	100%	–	–	50.00%	59.3%	–	78.1%	17.9%
Enterococcus spp.	36%	–	–	0%	0%	40%	100%	60%	66.7%
Psuedomonas spp.	–	100%	–	–	100%	90%	–	34.8%	50%
P. aureoginosa	100%	50%	–	–	75%	78.4%	–	81.8%	62%
K. pneumonia	100%	100%	–	–	55.6%	23.8%	–	25.5%	11.5%
CONS	100%	–	14.3%	4.5%	–	100%	–	50%	–
S. aureus	100%	–	54.5%	35%	0%	–	–	–	–
Enterobacter spp.	0.00%	–	–	–	33.3%	68.4%	100%	73.7%	47.1%
Acinetobacter baumannii	–	100%	–	–	10%	9.4%	–	9.8%	5.6%
Serratia marcescens	–	100%	–	–	33.3%	10%	–	24%	0%
Stenotrophomonas maltophilia	–	–	–	100%	96.4%	–	–	0%	–
Candida spp.	100%	–	–	–	–	–	–	–	–
Streptococcus spp.	100%	–	–	0%	–	–	–	–	–
Burkholderia cepacia	–	0%	–	–	50%	66.7%	–	0%	0%
Morganella morganii	–	–	–	–	–	100%	100%	100%	100%
Total	85.2%	96.9%	28.1%	14.7%	49.4%	44.8%	100%	43.0%	26.8%